Details

Autor(en) / Beteiligte

• Gonzalez, Daniel
• Amarilyo, G
• Ambler, W
• Armendariz, S
• Balevic, S
• Ballenger, L
• Basiaga, M
• Benham, H
• Beukelman, T
• Bullock, D
• Cooper, S
• Correll, C
• Corvalan, R
• Davis, A
• Davis, C
• De Ranieri, D
• Delnay, N
• Donaldson, B
• Dowling, J
• Du, Q
• Elder, M
• Federici, S
• Fennell, J
• Ferreira, B
• Fleming, C
• Flynn, O
• Gerstbacher, D
• Gotschlich, E
• Guittar, P
• Hammelev, E
• Hay, A
• Hekl, K
• Hill, P
• Hoffart, C
• Horwitz, M
• Huber, A
• Huttenlocher, A
• Joshi, S
• Jung, L
• Kessler, E
• Khalsa, U
• Kosikowski, A
• Kremer, C
• Lai, J
• Lapin, B
• Lee, T
• Lerman, M
• Luca, N
• Magni Manzoni, S
• McConnell, K
• McHale, I
• Miettunen, P
• Morgan, S
• Moussa, T
• Murphy, A
• Natter, M
• Neely, J
• Newhall, L
• Nicolai, R
• Oberle, E
• Olson, J
• Pagano, E
• Pardeo, M
• Patel, J
• Pooni, R
• Quinlan-Waters, M
• Rakestraw, A
• Ringold, S
• Roth-Wojcicki, E
• Sabbagh, S
• Sandborg, C
• Scalzi, L
• Scharnhorst, S
• Schmitt, E
• Sheets, R
• Shelly, A
• Shivers, C
• Sletten, J
• Spitznagle, J
• Stapp, H
• Stoll, M
• Sumner, J
• Szymanski, A
• Tambralli, A
• Tapani, S
• Tarvin, S
• Tate, L
• Torok, K
• Uriguen, S
• Varghese, C
• Vazzana, K
• Veiga, K
• Verbsky, J
• Vora, S
• Wahezi, D
• Waite, H
• Wright, T
• Yomogida, K
• Zartoshti, A
• Zeft, A

Titel

Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial

Ist Teil von

• Lupus science & medicine, 2022-11, Vol.9 (1), p.e000811

Ort / Verlag

England: Lupus Foundation of America

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• ObjectiveDetermine the pharmacokinetics (PK) and exposure–response of hydroxychloroquine (HCQ) and desethylhydroxychloroquine (DHCQ) in paediatric SLE (pSLE).MethodsWe conducted an exploratory phase 2, direct-to-family trial. Children enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry with a diagnosis of pSLE were eligible if they were receiving HCQ as standard of care for ≥3 months. Biological samples were collected at up to four visits over a 6-month period. At each visit, plasma was obtained to measure the concentrations of HCQ and DHCQ, as well as cytokines. HCQ and DHCQ plasma PK data were analysed using a population PK modelling approach.ResultsTwenty-five subjects provided a total of 88 plasma concentrations for PK analysis. There was a poor linear fit between HCQ concentrations and total body weight (R2=0.03). There was a decline in both interferon (IFN)-alpha and IFN-gamma with higher concentrations of HCQ and DHCQ. Volume of distribution for HCQ in plasma was higher in children compared with published values in adults (73 000 L vs 44 000 L), but clearance values in children were similar to adults.ConclusionsWe report the first population PK model for HCQ and DHCQ in children using data from a novel direct-to-family clinical trial. We observed high interindividual variability in HCQ PK and found that weight-based dosing for HCQ is poorly correlated with drug concentrations, suggesting the need to use therapeutic drug monitoring to individualise dosing. Furthermore, our results suggest that the current weight-based dosing paradigm for HCQ may result in suboptimal drug exposures, particularly for children with obesity. Accordingly, additional studies of HCQ are needed in pSLE to determine the optimal drug concentration and dosing to reduce disease activity and improve outcomes.Trial registration numberNCT04358302.